(Reuters) – Novavax Inc on Monday said it had begun to crossover patients in its ongoing COVID-19 vaccine trials in South Africa and the UK to ensure participants who previously received placebo also receive active vaccine.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
